Anti-PD1 treatment of advanced melanoma: development of criteria for a safe stop
Affiliation
Division of Cancer Sciences, University of Manchester and Christie NHS Foundation Trust, Manchester, UKIssue Date
2019
Metadata
Show full item recordCitation
Lorigan P, Eggermont AMM. Anti-PD1 treatment of advanced melanoma: development of criteria for a safe stop. Ann Oncol. 2019.Journal
Annals of OncologyDOI
10.1093/annonc/mdz182PubMed ID
31218362Additional Links
https://dx.doi.org/10.1093/annonc/mdz182Type
ArticleLanguage
enae974a485f413a2113503eed53cd6c53
10.1093/annonc/mdz182
Scopus Count
Collections
Related articles
- Combination anti-PD1 and ipilimumab therapy in patients with advanced melanoma and pre-existing autoimmune disorders.
- Authors: Brown LJ, Weppler A, Bhave P, Allayous C, Patrinely JR Jr, Ott P, Sandhu S, Haydon A, Lebbe C, Johnson DB, Long GV, Menzies AA, Carlino MS
- Issue date: 2021 May
- Ipilimumab in anti-PD1 refractory metastatic melanoma: a report of eight cases.
- Authors: Jacobsoone-Ulrich A, Jamme P, Alkeraye S, Dzwiniel V, Faure E, Templier C, Mortier L
- Issue date: 2016 Apr
- (18)F-FDG PET/CT based spleen to liver ratio associates with clinical outcome to ipilimumab in patients with metastatic melanoma.
- Authors: Wong A, Callahan J, Keyaerts M, Neyns B, Mangana J, Aberle S, Herschtal A, Fullerton S, Milne D, Iravani A, McArthur GA, Hicks RJ
- Issue date: 2020 May 14
- Immune checkpoint inhibitors-associated risk of immune-related hypothyroidism in older patients with advanced melanoma: a real-world analysis of US SEER-Medicare data.
- Authors: Almutairi AR, Erstad BL, McBride A, Slack M, Abraham I
- Issue date: 2021 Apr
- Efficacy of ipilimumab 3 mg/kg following progression on low-dose ipilimumab in metastatic melanoma.
- Authors: Lai-Kwon J, Jacques S, Carlino M, Benannoune N, Robert C, Allayous C, Baroudjian B, Lebbe C, Zimmer L, Eroglu Z, Topcu TO, Dimitriou F, Haydon A, Lo SN, Menzies AM, Long GV
- Issue date: 2023 Jun